Introduction {#S1}
============

Frontotemporal lobar degeneration (FTLD) represents a group of neurodegenerative brain diseases, characterized by relatively localized degeneration of the frontal and anterior temporal lobes. One of the clinical entities associated with FTLD is frontotemporal dementia (FTD), a neurodegenerative brain disorder with a diverse clinical presentation and multiple possible molecular pathways of disease. The prevalence of FTD is 1 to 461 per 100.000 individuals, accounting for approximately 2.7% of all dementias ([@B23]; [@B69]). In patients under 65 years, FTD accounts for approximately 10.2% of all dementias, and is the second most common dementia subtype after Alzheimer's disease (AD) in this age group ([@B69]).

Clinically, patients with FTLD display a progressive change in behavior, so-called behavioral variant FTD (bvFTD), and/or decline of language, or language variant presenting as primary progressive aphasias (PPA), such as semantic variant PPA (sv-PPA), non-fluent PPA (nfv-PPA), and logopenic PPA (lv-PPA) ([@B123]). There may be a symptomatic overlap with atypical parkinsonian disorders or motor neuron disease (MND) ([@B20]).

Upon post-mortem examination of the affected brain, FTLD is characterized by protein inclusions in degenerating neurons. The composition of these inclusions varies across the disease spectrum. The majority of patients (85%) show cellular inclusion bodies that are comprised of either tau (FTLD-tau) or trans-active response DNA binding protein of 43 kDa (TDP-43) (FTLD-TDP). The latter can be subdivided into FTLD-TDP A to E ([@B94]; [@B146]). Another subgroup of cases present with inclusions of the fused in sarcoma (FUS) protein (FTLD-FUS). In the remaining cases, inclusions are comprised of (hitherto unidentified) proteins of the ubiquitin proteasome system (FTLD-UPS) or, infrequently, no protein inclusions are found (FTLD-ni) ([@B94]; [@B135]). The latter has also been described as dementia lacking distinct histopathology (DLDH), a term introduced by [@B83] in patients with degeneration of the brain without the presence of neuronal inclusions or senile plaques. Many of these cases have since been reclassified, as they were later found to have neuronal inclusions staining positive for ubiquitin ([@B95]). The underlying disease mechanisms involved in this rare subtype are not yet fully understood.

In FTD, heritability plays a main role, with a positive family history in 39--50% of cases ([@B129]; [@B125]; [@B135]; [@B116]). An autosomal dominant presentation is seen in 10--23% of patients ([@B58]; [@B125]; [@B135]). The most frequent mutated genes involved in FTD with a dominant inheritance pattern are the *C9orf72* (8.2%) ([@B31]; [@B124]; [@B55]), the progranulin (*GRN*) (4.1%) ([@B7]; [@B25]; [@B135]) and the microtubule associated protein tau (*MAPT*) (5.6%) ([@B70]). Less frequent disease genes are those coding for the protein fused in sarcoma (*FUS*) ([@B160]; [@B32]), chromatin-modifying protein 2b (*CHMP2B*) ([@B145]; [@B73]), TAR DNA-binding protein (*TARDBP*) ([@B87]), TANK binding kinase 1 (*TBK1*) ([@B22]; [@B51]; [@B57]; [@B117]), valosin containing protein (*VCP*) ([@B155]), sequestosome 1 (*SQSTM1*) ([@B47]), and several others ([@B116]; [@B159]; [@B21]).

Amongst all of these heterogeneous subtypes in multiple domains, significant correlations can be found between causal gene, neuropathology and a certain set of clinical presentations. However, a one-to-one relationship is lacking ([@B135]; [@B146]).

The diagnosis of bvFTD and of the different language variants of FTD is most commonly based upon clinical diagnostic criteria ([@B63]; [@B123]). These are based on the presenting core symptoms, complemented with results of (a combination of) brain magnetic resonance imaging (MRI), 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan, perfusion single-photon emission tomography (SPECT) scan and DNA screening for causal mutations.

Several other techniques can aid in the differential diagnosis of FTD, especially when the clinical presentation is suggestive for other types of dementia as illustrated by our clinical vignette. To distinguish FTD from dementia caused by AD, cerebrospinal fluid (CSF) biomarkers demonstrating amyloid and tau pathology and amyloid tracer imaging techniques are widely used in clinical practice ([@B24]; [@B40]). Although these CSF biomarkers have a good diagnostic accuracy for AD, some cases display an atypical biochemical signature, as we will discuss below. Numerous other novel techniques are hitherto primarily carried out in a research setting.

Due to its heterogeneous nature, the diagnosis of FTD can be challenging. This review aims to summarize the state of the art in the current wide range of available diagnostic tools, covering neuropsychological evaluation, neurochemical and imaging biomarkers and genetic testing. More specifically, we will summarize the indications, evidence and added diagnostic and therapeutic value of these techniques within the framework of a clinical setting.

###### Clinical Vignette

A 65-year old patient consulted the neurologist with complaints of gradually progressive memory deficits.

Her previous medical history included arterial hypertension, surgical removal of an occipital meningioma and melanoma. Her medication intake was limited to a diuretic and a beta-blocker.

The presenting complaints were those of short term memory problems with insidious onset, progressively worsening over the course of 1 year. There was also occasional occurrence of diminished orientation in space.

The family history revealed that the maternal grandfather had late-onset dementia.

Clinical neurological examination was perfectly normal except for the presence of palmomental reflexes. No other frontal release signs, parkinsonism or any other pathological sign was found.

A diagnostic workup was performed:

1.  An extensive blood analysis showed no anomalies except for a slight macrocytic anemia. Thyroid function and blood vitamin levels were adequate.

2.  Neuropsychological testing revealed a single domain amnestic mild cognitive impairment.

3.  An MRI scan of the brain showed corticosubcortical atrophy, more than what would be expected for the patient's age ([Figure 1](#F1){ref-type="fig"}).

Based upon initial anamnestic presentation, the suspicion for prodromal early onset AD was raised.

During the next encounter, the patient was accompanied by her husband who mentioned that 1 year prior to the onset of the memory complaints, he had begun to notice behavioral changes. There was slight disinhibition, with the tendency to laugh at socially inappropriate occasions. In addition, the patient had developed apathy, of which loss of initiative was the most prominent symptom. There were some dysexecutive symptoms, with difficulties managing her everyday tasks. These symptoms had implications on the course of the activities of daily living (ADL), with a lack of personal hygiene and self-care. Only later during the disease course did the memory complaints also become apparent.

Paraclinical re-evaluation of the patient was performed:

1.  An automated volumetric analysis of the brain MRI scan showed a more pronounced atrophy of the frontal lobes in comparison with age-matched controls. The hippocampal volume was normal for age ([Figure 2](#F2){ref-type="fig"}).

2.  On an FDG PET scan of the brain, a significantly lower metabolism could be visualized anteromedially in the right frontal lobe and in the right temporal lobe. Minimal hypometabolism was found on the left side as well.

3.  CSF biomarker analysis revealed elevated T-tau (632 pg/ml; normal: \<501 pg/ml) and P-tau (69.5 pg/ml; normal: \<57 pg/ml) levels with normal values of Aβ~1--42~ (1551 pg/ml; normal: \>755 pg/ml) and Aβ~1--42~/Aβ~1--40~ ratio (0.196; normal: \>0.106). This result indicated the presence of a neurodegenerative brain disease, but made the diagnosis of an underlying AD less likely.

4.  Genetic testing of known causal AD and FTD genes was performed and could not identify a causal mutation.

These biomarkers were incompatible with the diagnosis of prodromal AD. Furthermore, a striking localized atrophy in the frontal lobe on the automated volumetric analysis of the brain MRI scan ([Figure 2](#F2){ref-type="fig"}) and a significantly lower metabolism in the right frontal and temporal lobes prompted the shift of focus to a possible FTD.

Based on the presenting clinical symptoms and the CSF and imaging biomarkers, the tentative diagnosis of behavioral variant FTD (bvFTD) was retained.

This case serves as an example of the importance of an extensive patient history as well as of specific biomarkers for the diagnosis of neurodegenerative brain disorders. Underneath an atypical clinical presentation, highly suggestive for prodromal AD, an underlying FTD could be unveiled.

![Brain MRI of the patient described in the clinical vignette.](fnins-13-00757-g001){#F1}

![Volumetric brain MRI of the patient described in the clinical vignette (report by Icometrix).](fnins-13-00757-g002){#F2}

Clinical Diagnostic Criteria for FTD: Strengths and Limitations {#S2}
===============================================================

The most recently revised consensus criteria for the clinical diagnosis of bvFTD are those by [@B123]. In this hierarchical framework, three levels of diagnostic certainty are distinguished. The first degree determines whether or not the term "possible" bvFTD is appropriate and is based upon presence of core symptoms (behavioral disinhibition, apathy/inertia, compulsive behavior, dietary changes and executive dysfunction with spared memory and visuospatial functions) alone. For "probable" and "definite" bvFTD, results of imaging and histopathology/DNA analysis, respectively, are taken into account. The consensus criteria for possible bvFTD have a sensitivity of 85--95% and a specificity of 82%, irrespective of the underlying proteinopathy ([@B123]; [@B68]; [@B8]). For probable bvFTD, sensitivity and specificity values are 75--85 and 95%, respectively ([@B123]; [@B68]; [@B8]). A higher sensitivity is reached in early onset dementia compared with late onset, as in younger age groups there is significantly more disinhibition, loss of empathy and compulsive behavior ([@B123]; [@B8]). False positive diagnoses are most common in patients with a later onset, an absence of family history for dementia and a more apathetic presentation. They mainly turn out to be AD upon neuropathological examination ([@B68]; [@B8]).

Several other clinical tools exist to measure frontal lobe dysfunction and therefore differentiate between FTD and AD. Many assessment batteries of neurobehavioral symptoms, such as the Schedules for Clinical Assessment in Neuropsychiatry ([@B158]), the Scale for Emotional Blunting ([@B102]), the Middelheim Frontality Score ([@B29]) and the Frontal Behavior Inventory ([@B79]) have a good discriminative ability ([@B105]; [@B98]).

Similar consensus criteria, with a stepwise approach to the level of evidence, exist for the language variants of FTD ([@B63]). The initial and most prominent symptoms should be deficits in language for the diagnosis of PPA to be considered. Subsequently, aphasia is characterized more specifically, distinguishing three separate entities: sv-PPA presenting with impaired comprehension but spared speech production, nfv-PPA with agrammatisms and speech apraxia, and lv-PPA with anomia and impaired single-word comprehension. The latter is only very rarely associated with FTLD; more commonly (77%) is it seen in patients with an underlying AD pathology ([@B20]; [@B92]; [@B138]).

Both false-positive and false-negative diagnoses of FTD are most often confounded with AD ([@B68]). Analysis of a large neuropathological confirmed cohort brought to light that several clinical characteristics can discriminate FTD from AD with great accuracy (\>86%); these were word finding difficulties, phonological errors, delusions and lack of object agnosia for AD, and relative lack of neuropsychiatric features, phonological errors and gait disturbance for FTD. Even then, about 36% of AD cases could not be differentiated from FTD based on clinical diagnostic criteria ([@B20]). 52% of AD patients with an atypical profile (commonly called "behavioral variant AD") meet the criteria for possible FTD, with apathy as the main overlapping feature ([@B112]). The notion that deficits in episodic memory can reliably distinguish FTD from AD used to be considered a strong criterion ([@B108]). However, many FTD patients do initially present with complaints of memory loss and often meet AD consensus criteria ([@B80]; [@B48]). Apart from AD, there is also substantial symptomatic overlap between FTD and MND, with co-occurrence of MND in 12.5--15% of FTD patients ([@B18]; [@B131]).

In many cases, some degree of parkinsonism is present upon initial presentation. When language and behavioral symptoms overlap, there is often a difficult differential diagnosis between so-called FTD with parkinsonism syndromes and atypical parkinsonian syndromes such as corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ([@B45]).

Another gray area exists along the borders of psychiatric disorders. An important limitation of the clinical diagnostic criteria is their relatively subjective and arbitrary nature. Symptoms like aberrant behavior are prone to observer bias, and are usually described by informants, making them inherently subjective and creating another layer of interaction in which nuances may be lost. Apathy, emotional withdrawal, hallucinations, delusions, psychosis, and compulsive behaviors can also easily be misdiagnosed as part of a psychiatric disorder such as depression, schizophrenia or bipolar disorder, especially with early onset dementia ([@B154]).

In summary, these commonly used sets of clinical criteria offer a framework for the standardized classification of patients with FTD into subtypes. However, overlap between categories and with other disorders may exist as well as mixed presentations, as the disease progresses and new symptoms arise.

Imaging Techniques to Diagnose FTD {#S3}
==================================

Structural Brain MRI {#S3.SS1}
--------------------

A typical first step in obtaining an imaging-supported diagnosis of FTD is structural brain MRI. T1-weighted MRI images aid in evaluating (localized) brain atrophy, while flair images provide proof of possible vascular damage. In FTD, one typically expects a more pronounced loss of volume in the frontal lobes and the anterior temporal lobes ([@B150]; [@B16]; [@B81]; [@B104]; [@B21]). Asymmetry is not uncommon, usually with a greater involvement of the dominant hemisphere, especially in language variants ([@B16]; [@B81]; [@B21]). The hippocampi and medial temporal lobes are typically relatively spared ([@B150]; [@B16]; [@B81]; [@B104]; [@B21]).

The aforementioned clinical subtypes of FTD generally have a distinct MRI atrophy pattern, although overlap exists. bvFTD patients typically show atrophy in the dorsolateral, orbital and medial frontal cortices as well as other regions of the salience network (SN) ([@B21]). sv-PPA patients show (often subtle) unilateral atrophy of the anterior temporal pole, with a characteristic "knife-edge" aspect in this area. Left-sided atrophy usually comes with a typical sv-PPA symptomatology, while patients with a predominantly right-sided atrophy tend to mimic bvFTD ([@B120]). The former is most common, but involvement of the contralateral side tends to occur within 3 years ([@B120]). nfv-PPA patients typically show volume loss in the left perisylvian region, more specifically the frontal operculum, premotor, and supplementary motor areas as well as the insula. Involvement of Broca's area explains the motor component of the aphasia ([@B118]; [@B21]). Comparable relatively specific patterns of atrophy exist within groups of carriers of the same causal mutation for FTD ([@B21]; [@B146]).

Sensitivity (se) and specificity (sp) of brain MRI for differentiating FTD from controls have been reported as 70--94 and 89--99%, respectively ([@B93]; [@B67]; [@B152]). Structural brain MRI is especially useful in distinguishing FTD from AD, with a sensitivity of 55--94% and a specificity of 81--97% by comparing patterns of atrophy ([@B16]; [@B93]; [@B67]). FTD patients show significantly more frontal and (mostly anterior) temporal atrophy with relative sparing of the hippocampus, while AD patients typically show bilateral hippocampal and medial temporal lobe atrophy, with relative sparing of the frontal lobes. Asymmetrical involvement of the hemispheres is another feature that is common in FTD patients and rare in AD ([@B150]; [@B16]; [@B93]). The left frontal and temporal regions are more often involved than the right in FTD ([@B16]). One study found that asymmetrical involvement of the brain differentiated FTD from non-FTD with a sensitivity of 38% and a specificity of 100% ([@B150]).

In the early stages of the disease, however, a brain MRI scan may not yet show abnormalities ([@B100]). One study showed an incongruence between clinical subtypes: almost half of bvFTD patients had normal MRI scans, while all of the sv-PPA patients displayed a pathological scan. However, not all scans analyzed were made at initial presentation ([@B81]). The presence of MRI abnormalities seems to be associated with more severe imitation behavior and disinhibition compared to those patients with normal MRI ([@B84]). On the other hand, a large-scale trial examining presymptomatic carriers of a known causal mutation was able to find structural imaging changes 5--10 years before expected onset, based on the average onset within the family. The insular and temporal cortices were the earliest regions to show atrophy ([@B126]).

Comparing brain atrophy and abnormalities is classically done by visual evaluation with commonly used scales such as the rating scale for medial temporal lobe atrophy (MTA) ([@B132]), the global cortical atrophy (GCA) scale ([@B113]) and the Fazekas' scale ([@B46]). However, novel fully automated image quantification methods such as automated volumetry, voxel-based morphometry (VBM), tensor-based morphometry (TBM), manifold learning, region of interest (ROI)-based grading and automated measuring of vascular burden are increasingly used. One study ([@B85]) showed an accuracy rate of respectively 50, 65, 64, 50, 58, and 33% for these techniques in differentiating between normal controls, AD, FTD and Lewy body dementia (LBD). However, in combining different techniques, accuracy rates of 69% were reached. FTD patients were most often misclassified as AD patients (21% of cases). Here, visual MRI ratings reached an accuracy of 52%, scoring significantly worse than combined automated quantification methods ([@B85]). A 2017 multi-centric MRI study found an accuracy rate of 85% for the diagnosis of bvFTD using automatic pattern recognition algorithms ([@B104]).

A study by [@B107] compared hippocampal volumetry (HV) with VBM and TBM in differentiation between controls, FTD patients and AD patients. FTD patients were rather accurately distinguished from controls with all techniques (se and sp were 84 and 80% for HV, 80 and 71% for TBM, 87 and 81% with VBM). VBM was most suitable for the differential diagnosis of FTD versus AD, with a sensitivity of 72% and a specificity of 67% ([@B107]). HV alone might be suitable to distinguish between FTD or AD and healthy controls, but in itself is not sufficient to differentiate between the two types of dementia (se and sp both 55%); here, a more extensive screening of the pattern of atrophy is needed ([@B107]; [@B30]).

These novel MRI techniques may aid in correctly identifying atypical presentations of neurodegenerative brain diseases. In AD patients with a predominantly behavioral or dysexecutive presentation, VBM shows marked atrophy in bilateral temporoparietal regions and only limited atrophy in the frontal cortex compared to controls, a pattern strikingly similar to AD patients with a typical presentation ([@B112]).

Another relatively new tool is the automated measurement of cortical thickness, which shows a specific pattern of cortical thinning in FTD compared to AD. This technique has similar results in differentiating FTD from AD as the more classically measured cortical volume ([@B38]). It is also useful to distinguish between clinical subtypes of FTD. One study showed distinct differences in cortical thinning between nfv-PPA and sv-PPA, resulting in an accurate diagnosis of 90% of cases ([@B3]).

Brain FDG PET and Perfusion SPECT Scan to Diagnose FTD {#S3.SS2}
------------------------------------------------------

Another part of the investigation of patients with suspected FTD is based on functional imaging of the brain ([@B123]). A commonly used technique is the FDG PET scan, which visualizes the cerebral glucose metabolism. Another method for functional imaging is perfusion SPECT, which also requires the intravenous injection of a radiolabeled tracer molecule, but instead is a measure of cerebral blood flow (CBF). The radiotracers most commonly used are ^99m^technetium-hexamethylpropylenamine oxime (^99m^Tc-HMPAO) or ^99m^technetium-ethyl-cysteinate dimer (^99m^Tc-ECD) ([@B6]).

In FTD, hypometabolism and hypoperfusion are typically seen in the frontal and anterior temporal lobes, more specifically in bilateral medial, inferior and superior lateral frontal cortices, anterior cingulate, left temporal, and right parietal cortices and the caudate nuclei. Usually, the hypometabolism correlates with, but often precedes, the atrophy on MRI ([@B150]; [@B89]; [@B106]). Local hypometabolism is best observed in the frontal regions for bvFTD, temporal regions for sv-PPA and perisylvian regions for nfv-PPA ([@B21]).

For FTD, the sensitivity of FDG PET scan ranges from 47 to 90%; the specificity from 68 to 98% ([@B50]; [@B78]; [@B152]). In subjects with late onset behavioral changes, bvFTD could be differentiated from other diagnoses with a sensitivity of 96% and a specificity of 73% when combined with structural MRI ([@B152]). An increase of the abnormalities can be seen over time, indicating the potential usefulness of FDG PET as a biomarker of disease progression ([@B34]).

The sensitivity and specificity of SPECT for the differential diagnosis between FTD and AD were reported as 36--100 and 41--100%, respectively ([@B36]; [@B161]; [@B6]). A Belgian study comparing SPECT abnormalities between cohorts of FTD and AD patients showed that biparietal hypoperfusion was significantly more present in AD, while bifrontal hypometabolism was significantly associated with FTD. 74% of AD patients and 81% of FTD patients were correctly classified ([@B114]). Another study showed that severely decreased frontal (se 76%, sp 60%) and temporal (se 71%, sp 55%) CBF and asymmetry between hemispheres (se 38%, sp 73%) were good markers to differentiate FTD from AD and vascular dementia (VaD) ([@B150]).

Thus, brain FDG PET or SPECT scans can significantly increase diagnostic accuracy and have the advantage of showing abnormalities fairly early in the disease process ([@B150]; [@B106]). A systematic review summarizing the evidence on the comparison of PET and SPECT for the diagnosis of neurodegenerative brain diseases showed that some studies find the techniques equally useful, while others describe better results with PET. However, there is a lack of methodologically good direct comparative studies. SPECT has the advantage of being more affordable whereas PET has a better spatial resolution ([@B28]).

Neurochemical Biomarkers to Diagnose FTD {#S4}
========================================

Core AD CSF Biomarkers: Aβ~1--42~, Aβ~1--42~/Aβ~1--40~ Ratio, T-tau and P-tau {#S4.SS1}
-----------------------------------------------------------------------------

The currently most used panel to assess pathological markers of neurodegenerative brain disease is a combination of amyloid-β of 42 amino acids (Aβ~1--42~), total tau protein (T-tau), and hyperphosphorylated tau (P-tau~181~) in CSF ([@B43]; [@B14]; [@B109]). They are not, in fact, used for the diagnosis of FTD, but rather to make the diagnosis of AD less likely when doubt exists. A CSF biomarker profile characteristic for AD, with good diagnostic accuracy (\>80%), shows decreased Aβ~1--42~ values, in combination with increased T-tau and P-tau values ([@B43]; [@B14]). Some patients do not completely match this typical AD CSF profile. As amyloid pathology is measurable much earlier in the disease process than tau pathology, there may be an isolated decrease in Aβ~1--42~ in early disease stages ([@B15]). CSF tau markers are more strongly associated with cognitive decline and disease progression in AD than Aβ~1--42~ ([@B111]). The opposite may also be true, as between-individual variations in total Aβ production or secretion from neurons and variations in CSF dynamics may cause Aβ~1--42~ to fall within a normal range, while underlying amyloid pathology is present ([@B15]).

In a large (*n* = 78) neuropathologically confirmed Belgian cohort of AD and non-AD dementia patients, the added diagnostic value for AD versus non-AD dementia (FTD amongst others) of the standard CSF biomarker panel to clinical consensus criteria was measured. In patients with an ambiguous (AD versus non-AD dementia) clinical diagnosis, the correct diagnosis would have been established in 67% of cases. As the diagnosis based on clinical consensus criteria was straightforward, no added diagnostic value could be measured. A misdiagnosis based on CSF biomarkers often occurs in patients with non-AD and AD co-pathology ([@B111], [@B109]). Apart from this, T-tau may also be significantly increased after stroke and in Creutzfeldt--Jakob's disease; whereas P-tau~181~ is a more specific CSF biomarker for AD. P-tau~181~ is indispensable for the differential diagnosis between AD and non-AD neurodegenerative brain disorders. Both Aβ~1--42~ and T-tau may be abnormal at intermediate levels in DLB, FTD, VaD, and CJD ([@B111], [@B109]). Sensitivity and specificity to distinguish FTD from AD have been reported as 74--100 and 82--97%, respectively ([@B72]).

To further improve diagnostic performance for AD, the use of the Aβ~1--42~/Aβ~1--40~ ratio has been proposed with good results ([@B76]; [@B90]; [@B110]; [@B14]), improving accuracy with 14--36% compared to Aβ~1--42~ alone ([@B76]; [@B91]). An isolated decrease in Aβ~1--42~ is more specific to AD, while a global decrease in both Aβ isoforms may be correlated with subcortical damage in general or may even be due to interindividual variability ([@B76]; [@B91]; [@B110]).

Cerebrospinal fluid biomarker analysis of the aforementioned proteins is fairly cost-effective ([@B111]). A disadvantage of all CSF biomarkers is the necessity to perform a lumbar puncture (LP). However, when performed correctly, LP has a low complication rate and a fairly good tolerability ([@B41]; [@B44]). Overall, evidence shows a clear indication for the use of CSF biomarkers Aβ~1--42~, Aβ~1--42~/Aβ~1--40~ ratio, T-tau and P-tau~181~ as an efficient measure to confirm or rule out AD when other biomarkers are inconclusive. FTLD cannot be diagnosed based on CSF biomarkers yet; non-specific, intermediate decreased Aβ~1--42~ and increased T-tau CSF levels may or may not be present.

Genetic Screening for Known Causal Genes for FTD {#S5}
================================================

It has been suggested that the presence of a pathogenic mutation in an FTD gene in a patient with suspected FTD should be enough to confirm a diagnosis of "definite" FTD, putting genetic screening at the same level of diagnosis as autopsy brain histopathology analysis ([@B123]). However, the absence of a mutation does not contribute to the diagnosis since FTD is frequently sporadic and FTD genes do not explain all families with FTD.

To elucidate further the value of genetic screening in clinical practice, we briefly outlined the known genotype--phenotype correlations of pathological mutations in the common FTD genes, including average age at onset and disease duration (overview in [Table 1](#T1){ref-type="table"}). We also mentioned the neuropathological correlation expected with each mutated gene, which is of particular interest when new disease-modifying therapies become available. The discovery of a mutation might mean a prognosis for the patient carrier and the presymptomatic family members. It may also guide the clinician in coupling a presenting clinical phenotype to a specific FTD gene.

###### 

Summary of genotype--phenotype correlations for gene defects most commonly associated with familial FTD.

  **Gene**   **Suggestive features**
  ---------- ----------------------------------------------------------------------------------------
  MAPT       \- bvFTD, FTD with parkinsonism, (PPA)
             \- No MND
             \- AAO 48--55 years
             \- Disease duration 9 years
  GRN        \- bvFTD (with apathy, social withdrawal), nfv-PPA
             \- Presence of hallucinations, apraxia and amnestic syndrome
             \- Presence of extrapyramidal symptoms; no MND
             \- Asymmetric atrophy and fast rate of whole brain atrophy on MRI
             \- Low serum progranulin
             \- AAO 53--65 years
             \- Disease duration 5--8 years
  C9orf72    \- bvFTD (nfv-PPA)
             \- Presence of MND
             \- Presence of psychiatric symptoms, bizarre behaviors, delusions,  OCD-like behaviors
             \- AAO 50--64 years
             \- Disease duration 2.5--14 years, dependent on ALS comorbidity
             \- Possible disease anticipation
  TBK1       \- bvFTD (with disinhibition, socially inappropriate behavior), (nfv-PPA,  lv-PPA)
             \- Presence of MND
             \- Presence of extrapyramidal symptoms, early memory impairment, psychiatric symptoms
             \- Asymmetric atrophy on MRI AAO 60--64 years
             \- Disease duration 4--8 years
  CHMP2B     \- bvFTD with early personality change, disinhibition
             \- Presence of parkinsonism, dystonia, pyramidal signs and  myoclonus; no MND
             \- AAO 58 years
  VCP        \- bvFTD (with apathy, emotional blunting, loss of initiative), SD
             \- Presence of IBM, PDB
             \- Presence of early psychosis, schizophrenia
             \- AAO 48--65 years
             \- Disease duration 6.5 years

MAPT {#S5.SS1}
----

Mutations in *MAPT*, located on chromosome 17, result in aberrant ratios of two of the six physiological isoforms of the tau protein. This disturbance in the equilibrium results in a disordered function of the cytoskeleton, affecting neuronal plasticity and axonal transport across the microtubules. It also leads to pathological tau aggregates, causing FTLD-tau. This association is not absolute, as *MAPT* mutations have been reported in the molecular pathogenetic pathways of PSP, CBD and, rarely, argyrophilic grain disease. The neuropathological correlations in these neurodegenerative brain disorders are distinct entities, with specific characteristics of the inclusion bodies as well as different localizations and distributions ([@B135]).

FTLD-tau usually presents as bvFTD with mostly disinhibition, repetitive and stereotyped behaviors, or as FTD with parkinsonism, although PPA variants have been reported ([@B59]; [@B134]; [@B135]; [@B137]; [@B21]). Clinical heterogeneity is considerable, between and within families. Patients are frequently misdiagnosed with AD ([@B122]; [@B59]). MND symptoms are uncommon. Symptoms develop at a particularly young age \[average age 48--55 years ([@B133], [@B134]; [@B59]; [@B119]; [@B135]), and range 25--65 years ([@B59])\]. Disease duration is 9 years on average (range: 5--20 years) ([@B134]; [@B135]).

GRN {#S5.SS2}
---

*GRN*, located on chromosome 17, neighboring *MAPT*, encodes for progranulin which is a multifunctional growth factor involved in cell proliferation, wound healing and inflammation regulation ([@B21]). Loss-of-function (LOF) mutations in *GRN* lead to autosomal dominant FTD ([@B7]; [@B25]; [@B135]; [@B21]), as they reduce progranulin levels by 50% resulting in *GRN* haploinsufficiency ([@B146]). *GRN* carriers generally present at autopsy with FTLD-TDP type A ([@B10]; [@B135]).

The clinical phenotype of *GRN* carriers is highly variable. Most commonly, patients present with bvFTD, frequently showing apathy and social withdrawal ([@B121]; [@B88]; [@B134]; [@B135]; [@B71]; [@B21]; [@B146]). Memory impairment is an early symptom ([@B121]; [@B59]). Several *GRN* carriers present with nfv-PPA and, less often, with a syndrome resembling lv-PPA ([@B121]; [@B10]; [@B135]; [@B71]; [@B137]; [@B146]). One study reported a remarkably high proportion of PPA presentations, outnumbering bvFTD ([@B149]). Parietal lobe dysfunction and atrophy are characteristic features of *GRN* carriers, as well as marked asymmetry and a fast rate of whole brain atrophy on MRI ([@B10]; [@B59]; [@B127]; [@B157]). Extrapyramidal symptoms are common, while signs of MND are rare. Diagnosis of AD and parkinsonian disorders associated with *GRN* have been reported ([@B121]; [@B88]; [@B59]; [@B134]; [@B135]; [@B71]; [@B21]; [@B146]). Hallucinations, apraxia and amnestic syndrome may be more specifically associated with *GRN* mutations ([@B88]; [@B134]).

The average onset age for *GRN* mutation-caused FTD is 53--65 years although highly variable (range: 35--89) ([@B121]; [@B10]; [@B133], [@B134]; [@B59]; [@B135]; [@B146]; [@B156]). The disease duration is shorter in *GRN* carriers than in *MAPT* carriers (average: 5--8 years) ([@B10]; [@B134]; [@B135]; [@B146]).

C9orf72 {#S5.SS3}
-------

The repeat expansion mutation in *C9orf72*, located on chromosome 9, is a major causal factor in the pathogenesis of both FTLD and ALS, forming a disease spectrum ([@B56]). The hexanucleotide repeat of G~4~C~2~ is expanded in patients and is generally considered to be pathological when the expansion contains ≥ 2--24 repeat units ([@B124]; [@B55], [@B54]; [@B146]). The exact mechanism of disease is unclear so far. Pathology may be due to haploinsufficiency or to gain-of-function, with toxic accumulation of the protein translated from the G~4~C~2~ repeat expansion as well as toxicity from the sense and antisense RNA foci transcribed from it ([@B55], [@B56], [@B54]; [@B135]; [@B146]).

At the neuropathology level, *C9orf72* expansion carriers mostly have FTLD-TDP type A or B. Rarely, FTLD-UPS and FTLD-TDP type C were found ([@B135]; [@B146]). Clinically, *C9orf72* expansion carriers display a wide array of symptoms. Clinical heterogeneity of patient carriers is seen between and within families ([@B96]; [@B135]; [@B146]). FTD and ALS phenotypes frequently exist alone, while a combination of FTD and ALS symptoms has been reported in 17--30% of the *C9orf72* carriers ([@B135]; [@B146]). When FTD is present, it is mostly bvFTD (\>65% of cases) with an early manifestation of executive dysfunction and some memory dysfunction, although PPA (most often nfv-PPA) has also been described (up to 30%) ([@B55]; [@B96]; [@B135]; [@B146]). Symptoms of abnormal behavior are also frequently observed, like delusions, repetitive and typically complex behaviors that mimic obsessive-compulsive disorder (OCD) and irrational, bizarre behaviors. There is an absence of the increased sweet food preference as typically seen in bvFTD ([@B137]; [@B146]). There is an especially high occurrence of psychiatric symptoms ([@B96]; [@B33]; [@B71]; [@B146]) and associated parkinsonism is common ([@B33]; [@B146]). The *C9orf72* expansion has also been identified in patients clinically diagnosed with AD, PD or Huntington disease phenocopy and several other disorders ([@B146]). This may partly be due to lack of typical neuroimaging features, which is not uncommon in carriers of the *C9orf72* expansion ([@B33]).

The mean onset age of symptoms for FTD caused by *C9orf72* expansion ranges between 50 and 64 years, but may be anywhere between 27 and 83 years of age ([@B96]; [@B149], [@B146]). Disease anticipation with decreasing onset ages in younger generations through expansion of the repeat size has been reported ([@B135]; [@B56]; [@B148], [@B146]). A significantly later onset age has been recorded in patients with a short (\<80 units; mean 62 years) compared to a long (\>80 units; mean 53 years) repeat size ([@B56]). When analyzing parent-offspring pairs, an earlier onset (16 to 25 years) was reported in the younger generation. Evidence for intergenerational repeat amplification has also been found, with an increase in expansion size of about 1000 units between a parent to their offspring and an intergenerational increase in methylation level of the 5′ flanking CpG island ([@B56]). One study analyzing onset ages in 36 families of *C9orf72* repeat expansion carriers showed significantly earlier mean onset ages across successive generations ([@B148]). Measuring of the exact repeat size has proved difficult because of its 100% GC content, its large size, somatic instability and the repetitive nature of its flanking sequences ([@B56]; [@B147]). This generates technical difficulties in measuring repeat sizes, requiring large quantities of high molecular weight genomic DNA ([@B147]). Recent novel technologies have enabled an increased resolution of the *C9orf72* expansion including the use of long-read sequencing ([@B42]).

The disease duration in *C9orf72* repeat expansion carriers is strongly dependent on ALS comorbidity ([@B146]). In pure FTD, progression is slow ([@B33]), average disease duration of 14 years was reported, which is much higher than the 2.5--3.6 years in pure ALS, resulting in a wide range of possible disease duration (1.7--22 years) ([@B96]; [@B135]; [@B146]).

TBK1 {#S5.SS4}
----

*TBK1*, localized on chromosome 12, encodes the TBK1 protein, a serine-threonine kinase involved in autophagy, neuroinflammation, and phosporylation of a wide range of substrates. LOF mutations in *TBK1* lead to 50% reduction of TBK1, which is associated with clinical ALS and FTD, and inherited in families in an autosomal dominant pattern ([@B51]; [@B57]; [@B149], [@B146]; [@B142]). The associated underlying pathology is FTD-TDP ([@B51]; [@B149]).

Over 50% of *TBK1* carriers have a clinical presentation of MND. About 25% present with pure FTD, mostly bvFTD (\>60%) but also nfv-PPA and lv-PPA ([@B57]; [@B149], [@B146]). Disinhibition and socially inappropriate behavior are more frequent than apathy ([@B149]). Extrapyramidal signs are common ([@B57]; [@B149], [@B146]), as are early impairment of memory and psychiatric symptoms ([@B149]). Structural MRI often shows marked asymmetry in atrophy ([@B149]).

A mean age at onset of 60--64 years (range: 35--78 years) has been reported in TBK1 carriers and disease duration ranged from 1 to 16 years, with an average of 4--8 years ([@B51]; [@B57]; [@B149], [@B146]; [@B142]).

Less Common FTD Genes {#S5.SS5}
---------------------

### CHMP2B {#S5.SS5.SSS1}

*CHMP2B*, located at chromosome 3p11.2, encodes a component of the heteromeric ESCRT-III complex with functions in the endosomal--lysosomal and the autophagic protein degradation pathway ([@B145]; [@B141]). Rare mutations were identified that resulted in a premature stop codon and C-truncating of the protein ([@B145]; [@B73]). Neuropathologically, *CHMP2B* carriers are associated with FTLD-UPS proteinopathy ([@B145]; [@B141]; [@B59]; [@B135]).

Clinically, *CHMP2B* carriers present commonly with bvFTD with early personality changes, frequently represented by less concern for others, an unkempt appearance, disinhibition, inappropriate emotional responses and restlessness which later can be accompanied by aggression. Apathy, hyperorality and motor symptoms such as parkinsonism, dystonia, pyramidal signs, and myoclonus occur later. MND is typically not present, although some cases have been reported ([@B59]; [@B73]; [@B134]; [@B135]). PPA syndromes have been described as well ([@B73]; [@B135]). The average onset age is 58 years, ranging between 46 and 65 years ([@B135]).

### VCP {#S5.SS5.SSS2}

*VCP*, located on chromosome 9 at 9p13.3, is associated with impaired functioning of an ATPase with a wide range of cellular functions. This impairment is due to missense mutations, of which \> 30 have been identified so far ([@B143]; [@B26]; [@B103]). Pathogenesis may occur because of a disturbance in the ubiquitin--proteasome mediated protein degradation, autophagy, or both ([@B143]; [@B135]). The associated neuropathological correlation is FTLD-TDP type D ([@B135]; [@B71]).

*VCP* carriers present with a specific clinical syndrome, combining FTD (present in 30% of cases) with inclusion body myopathy (IBM) (present in 90% of cases) and Paget's disease of the bone (PDB) (present in 50% of cases) in inclusion body myopathy with early onset Paget's disease and frontotemporal dementia (IBMPFD). Presentations may include any or all of these clinical entities, creating a disease spectrum. FTD symptoms usually fall within the category of bvFTD (with apathy, emotional blunting and loss of initiative and spontaneity) and sv-PPA ([@B135]; [@B146]). Psychotic signs and schizophrenia are common early symptoms. Parkinsonism is not uncommon ([@B146]). Other neurological diagnoses in *VCP* mutation carriers include PD, AD and, rarely, peripheral sensorimotor neuropathy, Charcot--Marie--Tooth disease type 2 and hereditary spastic paraplegia ([@B146]).

Age at onset is 48--65 years (range: 39--73 years), with a disease duration of 6.5 years ([@B59]; [@B135]; [@B146]). Onset age of FTD is considerably later than that of IBM and PDB ([@B146]).

Future Biomarkers for Improved Diagnosis of FTD {#S6}
===============================================

Imaging Biomarkers in a Research Setting {#S6.SS1}
----------------------------------------

### Diffusion Tensor Imaging {#S6.SS1.SSS1}

Diffusion tensor imaging (DTI) is an MRI imaging technique visualizing the diffusion of water molecules throughout the brain. It is used as a technique for white matter tractography ([@B97]).

Studies have shown that white matter damage is an early marker for disease in FTD, and DTI may be used as a tool to screen for such abnormalities at the presymptomatic stage ([@B35]; [@B97]; [@B77]). Reduced integrity of the uncinate fasciculus and anterior corpus callosum is typical for FTD, and the degree of damage is correlated to age and disease severity ([@B35]; [@B77]). Even here, specific patterns can be recognized for different clinical subtypes, and for carriers of different causal mutations. These abnormalities are consistent with characteristic brain atrophy distributions ([@B35]; [@B86]; [@B3]; [@B77]). The increase in white matter damage over time has been reported to be greater than that of gray matter atrophy, although only at the symptomatic stage, indicating the possible use of this technique as a marker for disease progression ([@B86]; [@B77]).

Studies comparing FTD cohorts with AD patients and with normal controls found significantly more white matter pathology mostly in bilateral uncinate fasciculus, cingulum bundle, and corpus callosum in FTD compared to both other groups ([@B97]; [@B9]). More studies are needed to consolidate these findings and define the diagnostic accuracy for FTD of DTI, as well as its power to distinguish FTD from other types of neurodegenerative brain diseases.

### Resting-State fMRI {#S6.SS1.SSS2}

In resting-state functional MRI (fMRI), regional connectivity is measured through fluctuations in blood-oxygen-level dependent (BOLD) signal. FTD patients, most often those with bvFTD, have decreased functional connectivity mostly in the SN, necessary for emotional processing, behavior and interpersonal experiences ([@B65]; [@B162]; [@B35]). A distinction can be made between FTD and AD, as in the latter a different pattern of loss of functional connectivity is seen involving the default mode network ([@B65]; [@B162]). The changes on fMRI are thought to be measurable at the presymptomatic stage. However, more research is needed to allow for a large scale application of this technique ([@B35]).

### Arterial Spin Labeling {#S6.SS1.SSS3}

Arterial spin labeling (ASL) is an MRI technique which, like SPECT, measures cerebral blood flow. It does so by magnetically labeling water molecules and has the advantages of being a method of functional brain imaging that is non-invasive and cost-effective, as no tracer molecule is necessary and it can easily be added to a routine structural MRI scan ([@B64]).

One of its clinical applications is the identification of regional hypoperfusion in neurodegenerative disease ([@B37]; [@B17]; [@B151]; [@B139]). Sensitivity and specificity to differentiate FTD from healthy controls have been reported as 78--79 and 76--92%, respectively. When distinguishing FTD from AD, these results were 69--83 and 68--93% ([@B139]; [@B140]). The accuracy in differentiating FTD from AD when ASL results are combined with structural MRI has been reported as 87% ([@B37]). However, its added value compared to structural MRI alone might be limited ([@B17]). In direct comparison to FDG PET, ASL came out as comparable ([@B151]; [@B140]).

### Tau PET Imaging {#S6.SS1.SSS4}

In recent years, amyloid PET scan measuring amyloid-β burden with tracers such as \[C-11\] Pittsburgh Compound B (PIB), flutemetamol, florbetapir (AV-45), florbetaben (AV-1), and AZD4694 has proven its value in quantifying underlying AD neuropathology. It is a well-established technique to confirm or rule out AD with great diagnostic accuracy. Abnormalities are present years before onset of symptoms, and this biomarker can be used as a measure for staging and monitoring of disease progression and distribution ([@B82]; [@B39], [@B40]; [@B130]; [@B75]).

No such imaging technique exists, yet, to confirm or rule out FTD. An extra hurdle here is the heterogeneity in underlying protein inclusions, as we mentioned earlier. For patients with an underlying FTLD-tau pathology, however, novel PET imaging techniques are being developed. The nature of the pathophysiology heightens the challenge in developing a useful ligand, as tau is a protein existing in six isoforms that undergo complex post-translational modifications. Moreover, the pathological tau aggregates \[neurofibrillary tangles (NFTs)\] are located intracellularly ([@B153]). Ligands such as \[18F\]THK523, \[18F\]THK5117, \[18F\]THK5105 and \[18F\]THK5351, \[18F\]AV1451(T807) and \[11C\]PBB3 have been proven to show the distribution of tau pathology *in vivo*. However, NFT are common in the pathophysiology of many other neurodegenerative brain diseases, such as AD, PSP, CBD, and chronic traumatic encephalopathy ([@B27]). Tau PET imaging also does not have the advantage of showing abnormalities at a presymptomatic stage, as there is a temporal relationship between tau-PET and symptoms. There is, however, a correlation between quantitative NFT burden and cognitive decline. Hence, through more research, tau PET imaging might be of use as a valuable marker for disease progression, staging and possibly therapeutic response ([@B27]; [@B153]).

### Electroencephalography {#S6.SS1.SSS5}

Electroencephalography is a non-invasive, simple, widely accessible technique that can be used to measure the physiological functionality of the brain, and disruption thereof in neurodegenerative brain disease ([@B2]; [@B61]).

Through quantitative analysis of EEG aberrations as opposed to more commonly carried out visual assessment, a more robust diagnostic value of this biomarker can be achieved. Accuracy of differentiating FTD from AD in patients with moderate to severe dementia has been reported as 79--100%, with a significantly lower frequency of the dominant frequency peaks in AD than in FTD, amongst other findings ([@B52]; [@B61]). Distinguishing FTD from healthy controls has proven more difficult, as EEG in FTD patients is usually relatively normal, especially in the early disease stages ([@B61]).

### Transcranial Magnetic Stimulation {#S6.SS1.SSS6}

Transcranial magnetic stimulation (TMS) is a painless, non-invasive procedure that assesses the cortical circuits and their function. An electromagnetic coil is placed on the scalp, where it generates a magnetic field. This induces a measurable electrical current in the brain, depolarizing the cells ([@B66]).

This technique has shown some value in the differential diagnosis of FTD, although results differ, cohorts are small and methodologies are difficult to compare ([@B115]; [@B4]; [@B74]; [@B11], [@B12]). The study with the largest scale so far is an Italian trial, where TMS differentiated FTD (*n* = 64) from AD (*n* = 79) with a sensitivity of 92% and a specificity of 89%, and FTD from healthy controls (*n* = 32) with a sensitivity of 90% and a specificity of 78% ([@B12]). However, their setup was only partially blinded, as the operator knew whether the subject was a healthy control or a patient, but not what clinical diagnosis had been given. The major differences in both diseases were an impairment of the short interval intracortical inhibition/intracortical facilitation (SICI-ICF) in FTD and an impairment of the short-latency afferent inhibition in AD ([@B19]; [@B12]). The same group also published findings of a distinct difference between healthy controls and presymptomatic *GRN* mutation carriers ([@B11]).

These results point to TMS as a possible early, non-invasive tool for diagnosis of FTD. More research is needed to consolidate this evidence.

Neurochemical Biomarkers in a Research Setting {#S6.SS2}
----------------------------------------------

### Neurofilament Light Chain {#S6.SS2.SSS1}

Neurofilament light chain (NfL) is a new candidate CSF and serum biomarker for the diagnosis of FTD. Neurofilaments are structural axonal proteins, and their presence in CSF is a marker for neurodegeneration ([@B60]).

Several studies have reported that CSF NfL levels are significantly increased in both FTD (se 78--84%, sp 82--100%) ([@B99], [@B101]; [@B1]) and AD in comparison with controls ([@B60]). However, NfL levels have been shown to be significantly higher in FTD than in AD, adding to the diagnostic accuracy achieved with a classic AD CSF biomarker panel alone ([@B1]; [@B60]). Pathologically confirmed FTLD-TDP patients have been reported as having higher NfL levels than those with FTD-tau (se 80%, sp 81%) ([@B128]; [@B1]), although other studies could not confirm these results ([@B60]; [@B101]).

Evidence for a good correlation between CSF and serum NfL levels exists, with a similar elevation in patients compared to healthy controls ([@B99]; [@B128]) and presymptomatic causal mutation carriers ([@B99]). NfL may also serve as a biomarker for disease severity and even rate of disease progression, and for conversion to the symptomatic stage in carriers of causal mutations ([@B99]; [@B128]).

### TDP-43 {#S6.SS2.SSS2}

As mentioned earlier, one of the molecular pathways leading to FTLD neuropathology is the intraneuronal aggregation of TDP-43, accounting for approximately half of all FTLD cases ([@B62]). The pathological protein has been proposed as a potential CSF biomarker specific to FTLD ([@B62]). Some difficulties have arisen, however. Because of low absolute levels of TDP-43 in biofluids, a very sensitive immunoassay is required, preferably specific for pathological TDP-43. Many different assays have already been developed, but their sensitivity and specificity are not yet well-established ([@B62]). Another obstacle is the occurrence of TDP-43 co-pathology in other neurodegenerative brain diseases, which may be present in 20--56% of patients with AD and other tauopathies, undermining the specificity of the biomarker ([@B5]; [@B62]).

### Progranulin {#S6.SS2.SSS3}

As we mentioned earlier, LOF mutations in *GRN* result in progranulin haploinsufficiency. Consequent decreased progranulin levels are detectable in plasma and CSF of carriers of such a causal mutation in *GRN*, both in patients with clinical FTD as in presymptomatic carriers, with a sensitivity and specificity of 100% ([@B53]; [@B49]; [@B136]; [@B60]).

Thus, dosage of plasma progranulin is a potential cheap and non-invasive tool for screening for carriers of genetic *GRN* defects. It is the only FTD-specific biomarker so far. However, given the small number of all FTD patients (both familial and sporadic) that carry a *GRN* mutation, its use may not be indicated for every patient in the initial diagnostic workup. The biomarker may be more useful in patients with a strong family history of FTD, although further genetic testing may then be required afterward, or to identify presymptomatic carriers amongst asymptomatic family members identified to have a causal *GRN* mutation. One must also take into account the region of origin of the patient, as *GRN* mutations represent a much larger share of all autosomal dominant FTD in certain regions (e.g., Belgium, Italy) than in others due to a founder effect ([@B144]; [@B121]; [@B13]). This factor may provide an additional indication for measuring plasma progranulin.

Conclusion: Recommendations for Daily Clinical Practice {#S7}
=======================================================

Making a correct and well-founded diagnosis of FTD is not an easy task, due to clinical heterogeneity and overlap with other neurodegenerative brain diseases. Atypical presentations are common, which is exemplified by our clinical vignette. A wide range of techniques exist to aid in the differential diagnosis, identifying characteristics of neuropsychology and biomarkers of neuroimaging, neurochemistry, and genetics. In this review paper, we have summarized current evidence for the diagnostic value of these techniques in differentiating FTD from other neurodegenerative diseases (mainly AD), and in differentiating between FTD subtypes. Taking this knowledge into account, we propose a stepwise approach in the diagnostic evaluation of a patient suspected to suffer from FTD ([Figure 3](#F3){ref-type="fig"}).

![Flowchart depicting a stepwise approach to the diagnosis of FTD. bv, behavioral variant; FTD, frontotemporal dementia; nfv-PPA, non-fluent variant primary progressive aphasia; AD, Alzheimer's disease; MND, motor neuron disease; NBD, neurodegenerative brain disease; PSP, progressive supranuclear palsy; IBM, inclusion body myopathy; PDB, Paget's disease of the bone; MRI, magnetic resonance imaging; FDG PET, fluorodeoxyglucose positron emission tomography; SPECT, single-photon emission computed tomography; CSF, cerebrospinal fluid; EP, extrapyramidal; AAO, age at onset.](fnins-13-00757-g003){#F3}

Firstly, obtaining the patient history and a standardized neuropsychological testing are necessary to establish the presence of a typical neuropsychological profile suggestive of FTD. Clinical consensus criteria for bvFTD as well as for PPA variants of FTD have a reasonably good accuracy in differentiating FTD from other diagnoses, although misdiagnosis (especially misidentifying FTD as AD and vice versa) is common. They aid in guiding the clinician's view by standardizing and quantifying the presenting symptoms and play a major role in establishing the correct diagnosis.

A second step indicated in any patient with a presentation of possible neurodegenerative brain disease is the acquisition of neuroimaging biomarkers. Structural brain MRI is most commonly used and typically shows a more pronounced loss of volume in the frontal lobes and the anterior temporal lobes. Asymmetry and sparing of the hippocampi and medial temporal lobes are accurate markers to differentiate FTD from AD. Evidence also shows that specific patterns of brain atrophy are associated with different clinical, neuropathological, and genetic subtypes of FTD. An important advantage of brain MRI is the good resolution in visualizing the brain tissue, with a possibility to screen for other organic causes of symptoms, such as brain tumors and hydrocephalus, and to quantify vascular lesions, making this a great choice as a first screening diagnostic technique. In recent years, novel techniques such as automatic volumetry, VBM, TBM, manifold learning, ROI-based grading, automated measurement of vascular burden and of cortical thickness have been developed to add to the diagnostic accuracy of structural MRI.

Functional neuroimaging through brain FDG PET or perfusion SPECT scans can also be considered in the initial diagnostic workup, as studies have shown high sensitivity and specificity to diagnose FTD. Hypometabolism and relative hypoperfusion are typically seen in the frontal and anterior temporal lobes, usually correlating with atrophy on MRI but often preceding it. Some studies have shown a greater accuracy of FDG PET when compared to SPECT, but the evidence is not very robust. For the clinician, the local availability of the techniques as well as cost-effectiveness (with SPECT being more affordable) also need to be taken into account.

When these imaging biomarkers are not sufficient to establish a clear diagnosis, and certainly in case of differential diagnostic doubt with (atypical presentation of) AD, we suggest a further exploration through the analysis of CSF biomarkers Aβ~1--42~, Aβ~1--42~/Aβ~1--40~ ratio, T-tau and P-tau~181~ that can indicate the presence of AD with good accuracy. FTD cannot be diagnosed based on CSF biomarkers, but non-specific, intermediate decreased Aβ~1--42~ and increased T-tau levels may or may not be present. The use of P-tau~181~ and the Aβ~1--42~/Aβ~1--40~ ratio significantly increases the accuracy of correctly identifying FTD vs. AD.

Lastly, we have elaborated on the genetic basis of FTD. To ascertain the possible presence of a causal mutation for FTD, a comprehensive family history complete with diagnoses, their level of certainty, age at onset and possible other related symptoms such as MND, parkinsonism and psychiatric disease should be inquired. When an autosomal dominant pattern of inheritance is suspected upon pedigree analysis or when the patient presents with an early onset age, screening for causal mutations may be indicated in the affected patient. We have summarized genotype--phenotype correlations for the most commonly involved genes (*C9orf72*, *MAPT*, *GRN, TBK1*) and some less frequent ones (*CHMP2B*, *VCP*), including average age at onset and disease duration ([Table 1](#T1){ref-type="table"}). We also mentioned the neuropathological correlation expected with each gene defect, which may be of particular interest when new disease-modifying therapies become available.

More research into novel biomarkers for the diagnosis of FTD and other neurodegenerative brain diseases is needed. Above, we have summarized current evidence on some novel imaging biomarkers (DTI, resting state fMRI, ASL, tau pet imaging, EEG, TMS) as well as neurochemical biomarkers (NfL, TDP-43, progranulin) ([Table 2](#T2){ref-type="table"}). These promising techniques are currently still only used in an experimental setting, or are not yet routinely implemented for screening in patients with suspected FTD.

###### 

Summary of potential future biomarkers to diagnose FTD.

  **Imaging biomarkers in a research setting**         
  ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  DTI                                                  \- MRI technique, visualizes white matter damage
                                                       \- Damage in bilateral uncinate fasciculus, cingulum bundle,  and corpus callosum are considered typical for FTD
                                                       \- Possibly also useful in presymptomatic stage
  Resting state fMRI                                   \- Measures regional connectivity through BOLD signal
                                                       \- Decreased connectivity in SN typical for FTD
                                                       \- Possibly also useful in presymptomatic stage
  ASL                                                  \- Functional MRI technique, measures  perfusion
                                                       \- Non-invasive, cost-effective (compared to FDG PET and  perfusion SPECT)
                                                       \- Good diagnostic accuracy
  Tau PET imaging                                      \- Quantifies NFT burden
                                                       \- Search for optimal ligand still ongoing
                                                       \- Abnormalities expected to be present in all tauopathies,  not specific to FTLD
                                                       \- Possibly also useful for staging and as marker for disease  progression
  EEG                                                  \- Not invasive, widely accessible
                                                       \- Good accuracy for differential diagnosis FTD-AD in  moderate to severe dementia, more evidence required in  early stage
  TMS                                                  \- Measures cortical circuitry through external  electromagnetic coil
                                                       \- Impairment of SICI-ICF typical for FTD
                                                       \- Possibly also useful in an early stage
  **Neurochemical biomarkers in a research setting**   
  NfL                                                  \- Marker suggestive of neurodegeneration
                                                       \- Measurable in both CSF and serum / plasma
                                                       \- Good diagnostic accuracy in research but clinical  validation needed
                                                       \- Possibly also useful for staging and as marker for disease  progression
  TDP-43                                               \- Marker of TDP-43 neuropathology
                                                       \- Specific to FTLD-TDP, although TDP co-pathology occurs  in other neurodegenerative brain diseases
                                                       \- Search for optimal antibody still ongoing
  Progranulin                                          \- Marker for *GRN* LOF mutation
                                                       \- Measurable in both CSF and plasma
                                                       \- 100% sensitive and specific to *GRN* mutation carriers
                                                       \- Indicated for screening in (pre)symptomatic possible  carriers of *GRN* defects
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